drug safety

Completing steps towards success checkmark on cubes symbolizing progress
Biotech

Sarepta shares safety update on DM1 RNA med

A drug safety group has delivered a positive review for an investigational siRNA being studied in a phase 1/2 trial for type 1 myotonic dystrophy.
Gabrielle Masson Nov 24, 2025 4:00pm
Intellia lab coat

Patient dies after receiving Intellia's CRISPR therapy

Nov 7, 2025 5:25am
pipeline pipes RD research

Incyte scraps BET inhibitor and anti-CD122 drug

Oct 28, 2025 9:05am
two green lights

CytomX reports patient death from kidney injury in ADC trial

Aug 14, 2025 6:45am
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Jul 31, 2025 9:10am
sarepta building
Favicon Fierce Pharma

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm